echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Alirocumab, an inhibitor of PCSK9, was successfully used in 9 later trials

    Alirocumab, an inhibitor of PCSK9, was successfully used in 9 later trials

    • Last Update: 2014-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: dingxiangyuan 2014-08-01 a new drug developed by Sanofi and its partner, Zaiyuan, can significantly reduce the level of "bad" cholesterol compared with placebo and existing treatment drugs in 9 later clinical trials Alirocumab, an injectable drug, is an inhibitor of PCSK9 and is being developed by Amgen and other pharmaceutical companies According to some industry analysts, if approved, the drugs could generate $3 billion or more in annual sales Odyssey showed that after 24 weeks of treatment, the average decrease percentage of LDL-C in patients treated with alirocumab was consistent with the previously observed results The subjects of the study were patients whose cholesterol levels were not adequately controlled by statins These patients could not tolerate statins or showed high or very high cardiovascular risk "These research strong data are the basis of our global listing information, and we expect to submit the listing application of the drug to the United States and the European Union by the end of the year," said Zerhouni, director of research and development of Sanofi PCSK9 inhibitors block a protein that prevents the body from removing LDL cholesterol from the bloodstream These drugs are mainly aimed at millions of patients who can't tolerate statins, such as fradiprotol or AstraZeneca rosuvastatin, or who can't control cholesterol level only by using statins When combined with statins, both alirocumab and Amgen's PCSK9 reduced LDL cholesterol by nearly 70%, which was higher than that of statins alone The drug is "generally well tolerated" in trials, with the most common side effects being nasopharyngitis, upper respiratory tract infections and injection site reactions There was a "basic balance" between serious adverse events and deaths in the treatment group A mid-term safety analysis showed that after 18 months of treatment, patients on alirocumab had a lower risk of cardiovascular events (cardiac death, myocardial infarction, stroke, and unstable angina requiring hospitalization) than those on placebo Alirocumab's potential to reduce cardiovascular risk is being evaluated in a long-term outcome trial involving 18000 patients Source address: http://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.